JO
CBIO

John Overdeck’s Crescent Biopharma CBIO Stock Holding History

John Overdeck’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.36M Buy
186,874
+71,046
+61% +$1.39M ﹤0.01% 2525
2026
Q1 		$2.13M Sell
115,828
-9,396
-8% -$108K ﹤0.01% 2710
2025
Q4 		$1.49M Buy
125,224
+96,906
+342% +$1.23M ﹤0.01% 2670
2025
Q3 		$337K Buy
+28,318
New +$376K ﹤0.01% 3169
2024
Q4 		– Sell
-446
Closed -$7.54K – 3310
2024
Q3 		$7.54K Buy
+446
New +$9.36K ﹤0.01% 3055
2024
Q1 		– Sell
-596
Closed -$141K – 3152
2023
Q4 		$141K Sell
596
-545
-48% -$84.7K ﹤0.01% 2902
2023
Q3 		$171K Sell
1,141
-756
-40% -$119K ﹤0.01% 2669
2023
Q2 		$330K Sell
1,897
-1,809
-49% -$303K ﹤0.01% 2488
2023
Q1 		$467K Buy
3,706
+1,522
+70% +$343K ﹤0.01% 2231
2022
Q4 		$662K Sell
2,184
-99
-4% -$14.6K ﹤0.01% 1899
2022
Q3 		$126K Sell
2,283
-940
-29% -$67.6K ﹤0.01% 2195
2022
Q2 		$193K Sell
3,223
-985
-23% -$72.9K ﹤0.01% 2174
2022
Q1 		$480K Sell
4,208
-1,895
-31% -$222K ﹤0.01% 2034
2021
Q4 		$879K Buy
6,103
+1,118
+22% +$203K ﹤0.01% 2676
2021
Q3 		$1.09M Buy
4,985
+2,729
+121% +$578K ﹤0.01% 2539
2021
Q2 		$523K Sell
2,256
-6,407
-74% -$1.63M ﹤0.01% 3055
2021
Q1 		$2.61M Buy
8,663
+910
+12% +$326K 0.01% 1499
2020
Q4 		$2.92M Buy
7,753
+4,687
+153% +$1.64M 0.01% 1256
2020
Q3 		$941K Sell
3,066
-1,664
-35% -$636K ﹤0.01% 1799
2020
Q2 		$1.78M Buy
4,730
+1,973
+72% +$559K 0.01% 1160
2020
Q1 		$629K Buy
2,757
+749
+37% +$286K 0.01% 1768
2019
Q4 		$1.06M Buy
2,008
+768
+62% +$416K ﹤0.01% 2125
2019
Q3 		$534K Buy
+1,240
New +$797K ﹤0.01% 2507
2019
Q1 		– Sell
-161
Closed -$152K – 3187
2018
Q4 		$152K Buy
+161
New +$194K ﹤0.01% 2765
2018
Q1 		– Sell
-229
Closed -$384K – 3284
2017
Q4 		$384K Buy
+229
New +$303K ﹤0.01% 2598

Other funds holding CBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

John Overdeck's CBIO Position: Q2 2026 in Review

John Overdeck increased its Crescent Biopharma (CBIO) stake by 61% in Q2 2026, buying an estimated $1.39M and bringing the position to 186,874 shares worth $3.36M. The position accounts for ﹤0.01% of the portfolio, ranked #2525.

John Overdeck first reported a position in CBIO in Q4 2017 and has held it in 25 quarters since. 81 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.

  • John Overdeck held 186,874 shares of Crescent Biopharma worth $3.36M as of Q2 2026.
  • John Overdeck bought 71,046 Crescent Biopharma shares in Q2 2026, an estimated $1.39M.
  • Crescent Biopharma made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2525 holding.
  • John Overdeck first reported a position in Crescent Biopharma in Q4 2017 and has held it in 25 quarters since.
  • 81 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.